Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Other: Placebo Administration
Other: Pharmacogenomic Study

First Posted Date: 2015-05-13

Last Posted Date: 2025-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT02443077

Locations: 🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States

and more 278 locations

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Goserelin
Drug: Enzalutamide
Device: mpMRI

First Posted Date: 2015-04-30

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT02430480

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

Phase 2

Completed

Conditions: Metastatic Leiomyosarcoma
Unresectable Leiomyosarcoma
Uterine Corpus Leiomyosarcoma

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Biological: Nivolumab

First Posted Date: 2015-04-28

Last Posted Date: 2025-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT02428192

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors

Phase 1

Suspended

Conditions: Neoplasms
Solid Tumors

Interventions: Drug: TdCyd

First Posted Date: 2015-04-22

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT02423057

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Phase 2

Terminated

Conditions: Ascites
Gastrointestinal Neoplasms
Ovarian Cancer
Ovarian Neoplasms
Gastrointestinal Cancer

Interventions: Drug: AZD9150

First Posted Date: 2015-04-16

Last Posted Date: 2017-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT02417753

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Natural History of Noncirrhotic Portal Hypertension

Recruiting

Conditions: Turner Syndrome
Cystic Fibrosis
Immunologic Deficiency Syndrome
Congenital Hepatic Fibrosis
Idiopathic Non-Cirrhotic Portal Hypertension

First Posted Date: 2015-04-16

Last Posted Date: 2025-06-03

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 400

Registration Number: NCT02417740

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

Phase 2

Completed

Conditions: Recurrent Lung Squamous Cell Carcinoma
Stage IV Lung Squamous Cell Carcinoma AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sapanisertib

First Posted Date: 2015-04-16

Last Posted Date: 2022-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT02417701

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 4 locations

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Phase 1

Completed

Conditions: Neurofibromatosis Type 1
Recurrent Primary Central Nervous System Neoplasm
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Visual Pathway Glioma
Refractory Primary Central Nervous System Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Pomalidomide

First Posted Date: 2015-04-14

Last Posted Date: 2022-04-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT02415153

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸
National Cancer Institute, Rockville, Maryland, United States

and more 9 locations

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Recruiting

Conditions: Kaposi Sarcoma
Recurrent Classic Hodgkin Lymphoma
Metastatic Malignant Solid Neoplasm
HIV Infection
Unresectable Solid Neoplasm
Advanced Malignant Solid Neoplasm
Anal Carcinoma
Lung Carcinoma
Refractory Classic Hodgkin Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Biological: Ipilimumab
Biological: Nivolumab
Procedure: Positron Emission Tomography

First Posted Date: 2015-04-06

Last Posted Date: 2024-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT02408861

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States

and more 31 locations

Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer

Phase 2

Terminated

Conditions: Endocrine Malignancy
Thyroid Cancer
Low-risk Papillary Thyroid Cancer

Interventions: Procedure: Total Thyroidectomy (TT)
Procedure: Prophylactic central neck lymph node dissection (pCND)

First Posted Date: 2015-04-06

Last Posted Date: 2022-09-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT02408887

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy